Department of Medicine, Biochemistry, Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Endocr Pract. 2013 Jan-Feb;19(1):100-6. doi: 10.4158/EP12325.OR.
To review available data on the efficacy and safety of bromocriptine-QR (BQR) and to consider its role in the management of Type 2 diabetes mellitus (T2DM).
Published literature reporting the efficacy and safety of BQR in the treatment of T2DM was reviewed, including peer-reviewed abstracts and poster presentations.
BQR is an oral hypoglycemic agent with a novel mechanism of action that appears to involve enhancement of morning central nervous system (CNS) dopaminergic activity, resulting in improved insulin sensitivity and reduced hepatic glucose output. Adjunctive treatment with BQR in the dosing range of 1.6 to 4.8 mg/d may result in a mean (95% confidence interval [CI]) reduction in glycated hemoglobin (A1c) levels of 0.69% (0.97%, 0.41%). Treatment with BQR appears to be associated with minimal intrinsic risk of hypoglycemia, and does not appear to be associated with clinically significant adverse effects on weight, triglycerides, free fatty acids, or blood pressure.
The favorable cardiovascular risk profile of BQR suggests that it may be useful in the treatment of patients with T2DM with a history of cardiovascular disease (CVD) or who have significant risk factors for CVD. However, knowledge of the efficacy and safety of BQR is limited by the relatively small clinical trials database. As a result, there is currently insufficient information on the safety and efficacy of adjunctive BQR in T2DM patients being treated with several common diabetes regimens (e.g., thiazolidinediones, insulin).
回顾溴隐亭 QD（BQR）在治疗 2 型糖尿病（T2DM）方面的疗效和安全性数据，并探讨其在 T2DM 管理中的作用。
对报道 BQR 治疗 T2DM 疗效和安全性的已发表文献进行了综述，包括同行评议的摘要和海报展示。
BQR 是一种具有新型作用机制的口服降糖药，似乎涉及增强早晨中枢神经系统（CNS）多巴胺能活性，从而提高胰岛素敏感性和降低肝葡萄糖输出。在 1.6 至 4.8mg/d 的剂量范围内辅助使用 BQR，糖化血红蛋白（A1c）水平平均（95%置信区间[CI]）降低 0.69%（0.97%，0.41%）。BQR 治疗似乎与低血糖固有风险极小相关，并且似乎与体重、甘油三酯、游离脂肪酸或血压的临床显著不良反应无关。
BQR 的良好心血管风险特征表明，它可能对有心血管疾病（CVD）病史或有 CVD 显著危险因素的 T2DM 患者有用。然而，由于相对较小的临床试验数据库，对 BQR 的疗效和安全性的了解有限。因此，目前关于辅助 BQR 在接受几种常见糖尿病治疗方案（如噻唑烷二酮类药物、胰岛素）的 T2DM 患者中的安全性和疗效的信息不足。
